CorMedix to Participate in Needham Virtual Healthcare Conference
Rhea-AI Summary
CorMedix (Nasdaq: CRMD) said senior management will participate in a fireside chat and investor meetings at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. The fireside chat is scheduled for April 14, 2026 at 3:00pm ET and will be available via webcast.
Positive
- None.
Negative
- None.
News Market Reaction – CRMD
In the Apr 7 session, CRMD gained 1.27%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Q4/FY25 earnings | Positive | -11.5% | Strong Q4 and 2025 results with profitability and reiterated guidance. |
| Mar 02 | Earnings date notice | Neutral | +1.1% | Announcement of Q4/FY25 earnings date and conference call details. |
| Feb 12 | Conference participation | Neutral | -0.9% | Management participation in three March 2026 healthcare investor conferences. |
| Feb 02 | Share repurchase | Positive | +5.3% | Authorization of up to $75M share repurchase program through 2027. |
| Jan 29 | Analyst day announcement | Neutral | +3.5% | Planned Analyst Day with portfolio, pipeline, and REZZAYO/DefenCath updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mostly aligned reactions to corporate events, but the strong Q4/FY25 earnings update was followed by a notable negative move, indicating that even positive fundamentals have not always translated into short-term price strength.
Over the last few months, CorMedix has transitioned into profitability, announced a $75M share repurchase, and provided strong Q4 and full-year 2025 results with pro forma revenue of $401.3M and net income of $163.0M. Despite this, the earnings release on Mar 5, 2026 saw a -11.52% reaction. The company also actively engages investors via analyst days and multiple conferences, making today’s Needham participation consistent with its ongoing investor-relations strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026.
| 25th Annual Needham Virtual Healthcare Conference | ||
| Date: | April 14, 2026 | |
| Time: | 3:00pm Eastern | |
| Format: | Fireside Chat | |
| Webcast: | Link to webcast | |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
